After promising M&A and buybacks to revive long-term prospects, Biogen refreshes board with three appointments to enthuse investors
Bruised by the titanic failure of its Alzheimer’s drug aducanumab and ahead of gene therapy competition for its flagship SMA treatment Spinraza, Biogen is fortifying its board with three new appointments to placate its increasingly disenchanted shareholder base that has seen the US drugmaker cultivate its pipeline around the now abandoned aducanumab.
Last Wednesday, company executives attempted to put a Band-Aid on the burn by telling analysts in a post-earnings conference call that they felt an “obligation to rebound” and intended to do so by engaging in M&A and buying back shares with the $42 billion they have in the bank, over the next five years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.